Peter J.M. Valk

Active 1997–2025

Also published as
Peter J. M. Valk
119
Papers
22,214
Citations
73
h-index
113
i10-index

Citations

Citations per year for Peter J.M. Valk1943: 1 citations1996: 2 citations1998: 3 citations1999: 1 citations2000: 6 citations2001: 3 citations2002: 7 citations2003: 11 citations2004: 42 citations2005: 78 citations2006: 98 citations2007: 93 citations2008: 129 citations2009: 128 citations2010: 157 citations2011: 268 citations2012: 278 citations2013: 295 citations2014: 268 citations2015: 276 citations2016: 279 citations2017: 269 citations2018: 227 citations2019: 860 citations2020: 727 citations2021: 816 citations2022: 659 citations2023: 559 citations2024: 837 citations2025: 381 citations2026: 9 citations1944–1995: no citations, so these years are not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,812 citing papers, 29.5% of this breakdownChina: 844 citing papers, 8.8% of this breakdownGermany: 781 citing papers, 8.2% of this breakdownUnited Kingdom: 608 citing papers, 6.4% of this breakdownNetherlands: 486 citing papers, 5.1% of this breakdownItaly: 440 citing papers, 4.6% of this breakdownFrance: 425 citing papers, 4.5% of this breakdownCanada: 332 citing papers, 3.5% of this breakdownSpain: 267 citing papers, 2.8% of this breakdownJapan: 233 citing papers, 2.4% of this breakdownAustralia: 220 citing papers, 2.3% of this breakdownSwitzerland: 178 citing papers, 1.9% of this breakdown
0%29.5%Other 20%

Fields

  • Medicine57.8%
  • Biochemistry, Genetics and Molecular Biology37%
  • Immunology and Microbiology2.9%
  • Neuroscience0.7%
  • Computer Science0.4%
  • Nursing0.3%
  • Other0.9%

Topics

  • Acute Myeloid Leukemia Research15.9%
  • Epigenetics and DNA Methylation7.3%
  • Histone Deacetylase Inhibitors Research3.4%
  • Cancer Genomics and Diagnostics3.3%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.3%
  • Acute Lymphoblastic Leukemia research3%
  • Other63.8%

Coauthors

All papers

Open in search
  1. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter J.M. Valk, Brent L. Wood, Roland B. Walter, Christian Thiede, Konstanze Döhner, Gail J. Roboz, Jacqueline Cloos - Blood 2021 cited by 718

  2. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2010 cited by 2,737

  3. A 17-gene stemness score for rapid determination of risk in acute leukaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2016 cited by 939

  4. Molecular Minimal Residual Disease in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 781

  5. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 290

  6. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2020 cited by 209

  7. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2018 cited by 205

  8. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 142

  9. A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Cell 2014 cited by 720

  10. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2020 cited by 153

  11. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Sockel, Malte von Bonin, Carsten Müller‐Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL) - Blood 2021 cited by 164

  12. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennita Slomp, Alexander N. Snel, Marie‐Christiane Vekemans, Bob Löwenberg, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis - Journal of Clinical Oncology 2013 cited by 449

  13. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ross L. Levine, Ari Melnick, Christopher E. Mason - Nature Medicine 2016 cited by 401

  14. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome

    Authors: , , , , , , , , , , , , , , - Cancer Cell 2016 cited by 239

  15. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern

    Authors: , , , , , , , , , , , , , , , , , - Blood 2011 cited by 335

  16. Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 84

  17. Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , - New England Journal of Medicine 2004 cited by 1,381

  18. Azacytidine Treatment for VEXAS Syndrome

    Authors: , , , , , , - HemaSphere 2021 cited by 79

  19. DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , - Cancer Cell 2010 cited by 833

  20. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan J. Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjørn Tore Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J.M. Valk, Catharina Van Elssen, Markus G. Manz, Yngvar Fløisand, Gert J. Ossenkoppele - Blood Advances 2021 cited by 66

  21. Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor.

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Huang, Y H, Chen, C W, Sundaramurthy, V, Słabicki, M, Hao, D, Watson, C J, Tovy, A, Reyes, J M, Dakhova, O, Crovetti, B R, Galonska, C, Lee, M, Brunetti, L, Zhou, Y, Brown, K T, Huang, Y, Cheng, X, Meissner, A, Valk, P J M, Van Maldergem, L, Sanders, M A, Blundell, J R, Li, W, Ebert, B L & Goodell, M A 2022, ' Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor ', Cancer Discovery, vol. 12, no. 1, pp. 220-235 . https://doi.org/10.1158/2159-8290.CD-21-0560, Huang , Y H , Chen , C W , Sundaramurthy , V , Słabicki , M , Hao , D , Watson , C J , Tovy , A , Reyes , J M , Dakhova , O , Crovetti , B R , Galonska , C , Lee , M , Brunetti , L , Zhou , Y , Brown , K T , Huang , Y , Cheng , X , Meissner , A , Valk , P J M , Van Maldergem , L , Sanders , M A , Blundell , J R , Li , W , Ebert , B L & Goodell , M A 2022 , ' Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor ' , Cancer Discovery , vol. 12 , no. 1 , pp. 220-235 . https://doi.org/10.1158/2159-8290.CD-21-0560 2021 cited by 63

  22. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2020 cited by 104

  23. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

    Authors: , , , , , , , , - Haematologica 2008 cited by 362

  24. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2019 cited by 139